Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR Positive/HER2 Low Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Not applicableLooking for participantsNCT07597993
What this trial is testing

BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Who this might be right for
Breast Cancer
AstraZeneca 109
Testing effectiveness (Phase 2)Looking for participantsNCT06207734
What this trial is testing

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120
Testing effectiveness (Phase 2)Looking for participantsNCT06837792
What this trial is testing

Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

Who this might be right for
Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
Yonsei University 141
Testing effectiveness (Phase 2)Looking for participantsNCT04553770
What this trial is testing

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast Cancer+4 more
Jonsson Comprehensive Cancer Center 88
Testing effectiveness (Phase 2)Looking for participantsNCT06486883
What this trial is testing

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

Who this might be right for
Advanced Breast CancerAdvanced Breast CarcinomaHormone Receptor Positive Breast Carcinoma
MedSIR 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07305246
What this trial is testing

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

Who this might be right for
Breast Cancer
First Hospital of China Medical University 120
Testing effectiveness (Phase 2)Looking for participantsNCT07497386
What this trial is testing

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Who this might be right for
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 150
Not applicableStudy completedNCT06040593
What this trial is testing

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-low Breast CancerHER2-negative Breast Cancer
Daiichi Sankyo 927
Large-scale testing (Phase 3)Active Not RecruitingNCT06144944
What this trial is testing

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Who this might be right for
Breast Cancer InvasiveHormone-receptor-positive Breast CancerHER2 Low Breast Carcinoma+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 160
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Not applicableStudy completedNCT07561346
What this trial is testing

Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer

Who this might be right for
HER2-zero, HER2-low and HER2-positive Tumors Distribution Across HR Expression Categories
Hellenic Cooperative Oncology Group 3,648
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07618923
What this trial is testing

Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer

Who this might be right for
Breast CancerHR Positive/HER2 Low Breast Cancer
Tang-Du Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04443348
What this trial is testing

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Who this might be right for
Triple Negative Breast CancerHormone Receptor Positive (HR+), HER2-negative Breast CancerBiopsy-proven, Positive Lymph Node(s)
Laura M. Spring, MD 120
Testing effectiveness (Phase 2)Looking for participantsNCT07498478
What this trial is testing

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Who this might be right for
Breast Cancer
TransThera Sciences (Nanjing), Inc. 94